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Abstract
Objective: Delayed cerebral ischemia (DCI) is an independent risk factor for
poor outcome after aneurysmal subarachnoid hemorrhage (SAH) and is multi-
factorial in etiology. While prior studies have suggested a role for matrix metal-
loproteinase-9 (MMP-9) in early brain injury after SAH, its contribution to the
pathophysiology of DCI is unclear. Methods: In the first experiment, wild-type
(WT) and MMP-9/ mice were subjected to sham or endovascular perforation
SAH surgery. In separate experiments, WT and MMP-9/mice were adminis-
tered vehicle or minocycline either pre- or post-SAH. All mice underwent
assessment of multiple components of DCI including vasospasm, neurobehav-
ioral function, and microvessel thrombosis. In another experiment, rabbits were
subjected to sham or cisterna magna injection SAH surgery, and administered
vehicle or minocycline followed by vasospasm assessment. Results: MMP-9
expression and activity was increased after SAH. Genetic (MMP-9/ mice)
and pharmacological (pre-SAH minocycline administration) inhibition of
MMP-9 resulted in decreased vasospasm and neurobehavioral deficits. A thera-
peutically feasible strategy of post-SAH administration of minocycline resulted
in attenuation of multiple components of DCI. Minocycline administration to
MMP-9/ mice did not yield additional protection. Consistent with experi-
ments in mice, both pre- and post-SAH administration of minocycline attenu-
ated SAH-induced vasospasm in rabbits. Interpretation: MMP-9 is a key player
in the pathogenesis of DCI. The consistent attenuation of multiple components of
DCI with both pre- and post-SAH administration of minocycline across different
species and experimental models of SAH, combined with the excellent safety profile
of minocycline in humans suggest that a clinical trial in SAH patients is warranted.
Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a form of
stroke associated with major morbidity and mortality.
Multiple pathophysiological processes occurring after
SAH contribute to the poor outcome seen in this patient
population. These injurious processes can broadly be cate-
gorized into early brain injury (EBI) and delayed cerebral
ischemia (DCI). EBI occurs in 12% of patients after SAH1
and is caused by a combination of transient global ische-
mia associated with abrupt increase in intracranial pres-
sure plus the toxic effects of blood in the subarachnoid
space. It is characterized by neuroinflammation, blood–
brain barrier (BBB) disruption, cerebral edema, and neu-
ronal cell death.2 DCI occurs in ~30–40% of patients after
SAH, is multifactorial in etiology, and is characterized by
delayed onset of ischemic neurological deficits and/or
radiographic evidence of cerebral infarction. The best
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characterized contributor to DCI is cerebral vasospasm,
wherein narrowing of large cerebral arteries occurs days
after SAH leading to reduced cerebral blood flow, cere-
bral ischemia, and in many cases frank cerebral infarc-
tion.3 In recent years, however, several lines of evidence
suggest additional contributors to DCI likely exist,
including microcirculatory autoregulatory dysfunction,
microvessel thrombosis, cortical spreading depression,
and delayed neuronal cell death.4,5 This more thorough
understanding of the numerous pathophysiological pro-
cesses contributing to secondary brain injury after SAH
has led many to conclude that development of a truly
efficacious SAH therapy will require identification of
molecular target(s) that contribute to numerous injuri-
ous pathways including ideally both DCI and EBI.4,5 It
is therefore essential that experimental studies explore
whether molecules(s) implicated in one injurious process
(e.g., EBI) also causally contribute to other injurious
processes (e.g., vasospasm-induced DCI and/or nonva-
sospasm contributors to DCI).
MMP-9 is a type IV collagenase that is involved in the
cleavage of a variety of substrates on the cell membrane
and extracellular matrix. It has been strongly implicated in
the pathophysiology of BBB disruption and cerebral edema
in several acute CNS injury paradigms including ischemic
stroke,6 traumatic brain injury,7,8 and more recently
SAH.9–19 However, the role of MMP-9 in SAH-induced
cerebral vasospasm and DCI is poorly understood. Numer-
ous studies have shown that MMP-9 levels and/or activity
are increased following SAH, both in patients and in animal
models.9,10,17,18,20–22 Regarding its role in EBI, several
investigators have found that pharmacologically inhibiting
MMP-9 via SB3CT and minocycline reduces EBI and
improves neurological deficits after SAH,13,15,16,19 although
both these pharmacologic agents are known to inhibit other
matrix metalloproteinases such as MMP-2. MMP-9 has
been more directly implicated in EBI after SAH when stud-
ies found that mice having genetic deletion of MMP-9
developed markedly less BBB disruption, cerebral edema,
and neurological deficits after SAH.14
Regarding the potential role of MMP-9 in DCI after SAH,
several clinical studies have examined the correlation
between MMP-9 levels and radiographic vasospasm and/or
clinical DCI, with conflicting results. Two laboratory studies
have also examined the potential role of MMP-9 in cerebral
vasospasm. The first reported a decrease in hemolysate-
induced contractility of cultured smooth muscle cells
(SMCs) with the MMP-2/MMP-9 inhibitor, SB-3CT.12 The
second reported an increase in MMP-9 expression in the
basilar artery of rats subjected to cisterna magna injection
SAH and a decrease in basilar artery vasospasm with pre-
SAH intracisternal injection of MMP-2/MMP-9 inhibitor,
SB-3CT.23 Neither study utilized genetic approaches to
directly interrogate the role of MMP-9 (a critical point given
the lack of an available specific MMP-9 pharmacological
inhibitor), and neither examined anti-MMP-9 agents when
delivered at clinically relevant time points after SAH (an
important point given the overall hope that these observa-
tions might ultimately lead to a novel therapy for SAH
patients). Overall, the aforementioned preclinical and clini-
cal investigations into the role of MMP-9 in SAH-induced
cerebral vasospasm and DCI certainly suggest that MMP-9
may play a key pathophysiological role; however, a definitive
causal contribution for MMP-9 in these injurious processes
is yet to be firmly established.
Therefore, in this study, we critically examined the
mechanistic role of MMP-9 in the pathogenesis of cere-
bral vasospasm and DCI after SAH using transgenic mice
having targeted genetic deletion of MMP-9. We then eval-
uated the translational potential of MMP-9-directed ther-
apy in two complementary animal models of SAH by
administering the broad MMP inhibitor, minocycline (an
FDA-approved drug with a proven safety profile in
humans including those with ischemic stroke) at clinically




Twelve- to fourteen-week-old male wild-type C57BL/6
mice were obtained from Jackson Laboratories (Bar Har-
bor, ME). MMP-9/ mouse breeders were obtained from
Jackson Laboratories (Strain #007084) and a colony was
established at our institution. Twelve- to fourteen-week-
old male MMP-9/ mice on C57BL/6 background were
used for experiments, with age- and gender-matched
wild-type C57BL/6 mice serving as controls. All studies
were approved by the Animal Studies Committee at
Washington University School of Medicine.
Twelve-week-old male New Zealand white rabbits were
purchased from the Animal Center of the Chinese Academy
of Sciences (Shanghai, China). All studies involving rabbits
were approved by the Animal Care and Use Committee at
Nanjing University and performed at that institution.
Experimental SAH
Experimental SAH was induced in mice by the endovas-
cular perforation technique as previously described.27–29
Briefly, mice were anesthetized with isoflurane (2%
induction, 1.5% maintenance). A 5-0 nylon suture was
introduced into the external carotid artery (ECA) and
advanced through the internal carotid artery (ICA) until
the ICA bifurcation was encountered. The suture was
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then advanced 5 mm further to cause SAH. The suture
was then removed and the ECA was ligated. Mice were
then allowed to recover from anesthesia in an incubator
and then returned to their cages. Mice that underwent
sham surgery had all the steps performed except for
suture advancement beyond the ICA bifurcation.
Experimental SAH was induced in rabbits according
to the cisterna magna double-hemorrhage method as
previously described.30,31 The rabbits were anesthetized
with intramuscular injection of ketamine (25 mg/kg)
and droperidol (1.0 mg/kg). A 23-gauge butterfly needle
was then inserted percutaneously into the cisterna
magna. After withdrawal of 1.5 mL of cerebrospinal
fluid, the same amount of nonheparinized fresh autolo-
gous auricular arterial blood was slowly injected into the
cisterna magna over 1 minute. The animals were then
kept in a 30° head-down position for 30 minutes. After
recovery from anesthesia, they were returned to their
housing. Forty-eight hours after the first SAH, a second
injection was performed in the same manner as the first.
In rabbits that underwent sham surgery, the same tech-
nique was applied with injection of sterile saline instead
of blood.
Drug administration
Mice (45 mg/kg in PBS) and rabbits (3 mg/kg in PBS)
were administered minocycline every 12 h, starting 2 h
prior to SAH for the pre-SAH treatment groups. For
post-SAH treatment groups, the same dose of minocy-
cline was administered every 12 h starting 1 h after SAH.
Vehicle-treated animals were administered equal volumes
of PBS. Drugs were administered intraperitoneally in mice
and subcutaneously in rabbits. In pilot studies, minocy-
cline administration to Sham-operated mice and rabbits
did not induce any changes in body weight, vessel diame-
ter, and neurological function, and this group was there-
fore not included in subsequent experiments.
Neurobehavioral tests
Neurobehavioral outcome in mice was examined daily
using Neuroscore and Rotarod tests, as previously
described.27–29 Briefly, neurological function was graded
based on a motor score (0–12) that evaluated sponta-
neous activity, symmetry of limb movements, climbing,
balance and coordination, and a sensory score (4–12) that
evaluated body proprioception and vibrissae, visual, and
tactile responses. Balance and coordination were assessed
by performance on rotarod (Rotamex-5, Columbus
Instruments, Columbus, OH). Mice were pretrained on
the rotarod 1 day prior to surgery. Latency on three trials
of 180 sec was averaged daily.
Vasospasm assessment
Vasospasm assessment in mice was performed on post-
surgery day 3 via cerebrovascular casting, as previously
described.27–29 Briefly, mice were anesthetized with isoflu-
rane, and transcardially perfused with PBS, 4% formalin,
and 3% gelatin-India ink solution. Brains were removed,
SAH was graded as previously described, and blood ves-
sels imaged under a microscope using a CCD camera.
The narrowest diameter within the first 1000 lm of the
middle cerebral artery (MCA) outside the lateral sulcus
was measured to assess vasospasm.
Vasospasm assessment in rabbits was performed by
measurement of basilar artery lumen area as previously
described.30,31 Briefly, rabbits were anesthetized with an
intramuscular injection of ketamine (40 mg/kg) and
droperidol (2.5 mg/kg), endotracheally intubated, and
mechanically ventilated. A thoracotomy was performed,
and transcardiac perfusion was initiated with 500 ml of
physiologic PBS (pH 7.4) at 37°C, followed by 500 mL of
10% buffered formaldehyde. A constant perfusion pres-
sure of 120 cm H2O was maintained. After perfusion-
fixation, the whole brain with intact circle of Willis was
removed and fixed further by immersion in 10% buffered
formaldehyde for 24 h. The formalin-fixed and paraffin-
embedded basilar artery sections (4 lm in thickness) were
stained with hematoxylin and eosin. Cross-sectional areas
were then obtained from photomicrographs of three
regions of the basilar artery (proximal, middle, and distal)
by a blinded investigator using the High Definition Medi-
cal Image Analysis Program (HMIAP-2000, developed by
Tongji Medical University, Wuhan, China).
MMP-9 zymography
MMP-9 activity was determined by the gelatin zymogra-
phy method as previously described.32 Briefly, frozen
brain tissue samples were homogenized and centrifuged
(10,000 g), and the resulting supernatant was used for
analysis. The supernatant was incubated with Gelatin-
Sepharose 4B (Pharmacia Biotech, Uppsala, Sweden) for
1 h with constant shaking. After centrifugation, the Gela-
tin-Sepharose pellet was rinsed with 500 lL of buffer con-
taining 50 mm Tris-HCl, pH 7.6, 150 mm NaCl, 5 mm
CaCl, 0.05% Brij-35, and 0.02% NaN3. The solution was
centrifuged again and the pellet was incubated for 30 min
with 50 lL of elution buffer consisting of 50 mm Tris-
HCl, pH 7.6, 150 mm NaCl, 5 mm CaCl, 0.05% Brij-35,
0.02% NaN3, and 10% dimethylsulfoxide (DMSO). Each
25 lL of the eluted sample was mixed with 25 lL of 2X
nonreducing sample buffer (0.125 mol/L Tris-HCl, 20%
glycerol, 4% SDS, 0.003% bromophenol blue, pH 6.8),
loaded onto 7.5% SDS-PAGE containing 0.1% gelatin,
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and electrophoresed at 100 V. Recombinant human
MMP-2 and MMP-9 (0.1–0.5 ng; EMD Bioscience) was
used as positive controls to identify the pro- and active
forms of MMP-2 and MMP-9. The gels were then washed
twice in 2.5% Triton X-100 for 20 min each followed by
incubation for 20 h at 37°C in a buffer containing
20 mmol/L Tris-HCl pH 7.6, 10 mmol/L CaCl2, and
0.04% NaN3. After incubation, the gels were stained for
1 h with 0.1% Coomassie Blue (diluted with 40% metha-
nol and 10% acetic acid) and destained until clear prote-
olytic bands appeared on a contrasting blue background.
Quantitative polymerase chain reaction
(qPCR)
qPCR was performed as previously described.29 Briefly,
messenger RNA (mRNA) was extracted from the ipsilat-
eral cerebral cortex using TRIzol (ThermoFisher Scientific,
Waltham, MA), followed by cDNA synthesis using High
Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems, Foster City, CA). The following oligonu-
cleotide primer pairs were used for qPCR: MMP-2 (For-
ward: 50-AACACCGAGGACTATGACCG-30, Reverse: 50-C
CACAC CTTGCCATCGTT-30), MMP-9 (Forward: 50-GA
TCCCCAGAGCGTCATTC-30, Reverse: 50-CCACCTTGTT
CACCTCATTTTG-30), and GAPDH (Forward: 50- CTTT
GTCAAGCTCATTTCCTGG-30, Reverse: 50-TCTTGCTCA
GTGTCCTTGC-30). The qPCR reactions were performed
on a 7500 real-time PCR System (Applied Biosystems,
Foster City, CA) using SYBR Green PCR Master Mix
reagents (Applied Biosystems, Foster City, CA). The
expression of GAPDH served as an internal control. The
delta-delta calculation method was used to calculate fold
change relative to sham controls.
Immunohistochemistry
Immunohistochemistry for assessment of microvessel
thrombi was performed as previously described.27–29
Briefly, mice were transcardially perfused with heparinized
PBS, whole brains were extracted and fixed by immersion
in 4% paraformaldehyde for 48 h, followed by coronal
slicing with 50 lmol/L thickness. Nine equally spaced
coronal sections from the frontal lobe to posterior parietal
lobe were then blocked in PBS containing 1% bovine
serum albumin, 0.2% dry milk, and 0.1% Triton-X100
for 1 h, followed by overnight incubation at 4C with
rabbit anti-fibrinogen antibody (1:1000 dilution; Abcam,
Cambridge, MA). The free-floating sections were then
incubated with biotinylated goat-anti Rabbit antibody
(Biorad, Hercules, CA) at room temperature for 2 h, fol-
lowed by incubation with VECTASTAIN Elite ABC Kit
solution (Vector Laboratories, Inc., Burlingame, CA), and
3,30-Diaminobenzidine tetrachloride (DAB) solution.
Images of the brain sections were obtained using Hama-
matsu NanoZoomer 2.0 HT system (Hamamatsu Photon-
ics, Shizuoka, Japan).
Statistical analysis
Data represent individual animals and are expressed as
mean  SEM. After testing for normality, data from
qPCR, vessel diameter and area measurements, MMP
zymography, and microvessel thrombosis quantification
were analyzed by Student’s t-test for experiments involv-
ing two groups and by one-way ANOVA followed by
Tukey’s multiple comparisons post hoc test for experi-
ments involving three or more groups. Neuroscore data
were analyzed using repeated measures ANOVA and
Figure 1. SAH induces an increase in MMP-9 expression and activity.
(A) Wild-type mice were subjected to sham or endovascular
perforation SAH surgery. MMP-9 RNA levels were assessed by qPCR in
the ipsilateral cortex at 24 and 72 h after SAH. Data represent
mean  SEM. *P < 0.05 vs. Sham, by one-way ANOVA with Tukey’s
multiple comparisons test. N = 5 per group. (B) WT mice were
subjected to sham or endovascular perforation SAH. MMP-9 activity
was assessed in the ipsilateral cortex at 72 h after SAH by gelatin
zymography. Representative zymogram images are at the top. Data
represent mean  SEM. *P < 0.05 vs. Sham, by Mann–Whitney U
test. N = 6 and 5 per group, respectively. WT, wild type.
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Newman–Keuls post hoc test for multiple comparisons.
Nonparametric data with two groups were analyzed using
Mann–Whitney U test. A P < 0.05 was considered as sta-
tistically significant.
Results
SAH increases MMP-9 expression and
activity
WT mice subjected to SAH demonstrated 2.9  0.2-fold
increase in MMP-9 mRNA at 24 h after SAH, and
3.2  0.3-fold increase in MMP-9 mRNA at 72 h after
SAH (P < 0.05 vs. Sham, Fig. 1A). On zymography, there
was a 4.0  1.4-fold increase in MMP-9 activity in the
ipsilateral hemisphere of mice subjected to SAH com-
pared to sham-operated mice (P < 0.05, Fig. 1B).
Genetic inhibition of MMP-9 attenuates
SAH-induced vasospasm and
neurobehavioral deficits
WT mice subjected to SAH exhibited significant cerebral
vasospasm on Day 3 after endovascular perforation SAH
(23  11%, P = 0.04) (Fig. 2A and B). In contrast,
MMP-9/ mice did not develop significant vasospasm
(2  11%, P = 0.8 vs. Sham; P = 0.02 vs. MMP-9+/+
SAH) (Fig. 2A and B). Similarly, WT mice subjected to
Figure 2. Genetic inhibition of MMP-9 attenuates SAH-induced neurovascular dysfunction. Wild-type (MMP-9+/+) and MMP-9 knockout (MMP-
9/) mice were subjected to sham or endovascular perforation SAH surgery. Large artery vasospasm was assessed on post-SAH Day 3 via
measurement of left middle cerebral artery (MCA) diameter. (A) Representative images of left MCA ipsilateral to endovascular perforation (white
arrowhead) (B) Left MCA vessel diameter measurements. Data represent mean  SEM. *P < 0.05 and n.s. P> 0.05 by one-way ANOVA with
Tukey’s multiple comparisons test. (C) Neurobehavioral testing was performed at baseline prior to SAH (Day 0) and daily for 3 days via
Neuroscore test. Data represent mean  SEM. *P < 0.05 vs. MMP-9+/+ Sham, #P < 0.05 vs. MMP-9/ Sham, &P < 0.05 vs. MMP-9+/+ SAH by
repeated measures ANOVA with Newman–Keuls multiple comparisons test. N = 7, 14, 6, and 21 for MMP-9+/+ Sham, MMP-9+/+ SAH, MMP-9/
Sham, and MMP-9/ SAH, respectively.
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SAH exhibited significant neurobehavioral deficits on
post-SAH days 1, 2, and 3 (P < 0.05) (Fig. 2C). In con-
trast, neurobehavioral deficits after SAH were milder on
post-SAH days 2 and 3 in MMP-9/ mice when com-
pared to WT mice that underwent SAH (P < 0.05 vs.
MMP-9+/+:SAH). The degree of neurobehavioral deficits
in these mice was not statistically significant on post-SAH
days 2 and 3 when compared to mice that underwent
sham surgery (P > 0.05 vs. MMP-9/ Sham) (Fig. 2C).
Minocycline attenuates SAH-induced
increase in MMP-9 activity
Vehicle-treated WT mice that were subjected to SAH
exhibited a 4.8  1.0-fold increase in MMP-9 activity
compared to mice that underwent sham surgery
(P < 0.05) (Fig. 3A and B). The increase in MMP-9 activ-
ity after SAH was attenuated (2.7  0.6-fold increase,
P < 0.05 vs. SAH-vehicle, P > 0.05 vs. Sham) in minocy-
cline-treated mice (Fig. 3A and B). MMP-2 activity did
not differ between the three groups (P > 0.05) (Fig. 3A).
Taken together, these results suggest that the effect of
minocycline in experimental SAH primarily involves
MMP-9 inhibition.
Pre-SAH minocycline treatment attenuates
SAH-induced vasospasm and
neurobehavioral deficits
Vehicle-treated WT mice that were subjected to SAH
exhibited significant cerebral vasospasm on post-SAH Day
3 (P < 0.05 vs. Sham, Fig. 4A and B). In contrast, treat-
ment with minocycline, starting 1 h prior to SAH, signifi-
cantly attenuated SAH-induced vasospasm (P > 0.05 vs.
Sham, P < 0.05 vs. SAH, Fig. 4A and B) in WT mice.
Similarly, vehicle-treated WT mice that were subjected to
SAH experienced marked neurobehavioral deficits
(P < 0.05 vs. Sham on post-SAH days 1, 2, and 3),
whereas minocycline-treated mice experienced signifi-
cantly less neurobehavioral deficits (P < 0.05 vs. SAH:
Vehicle on post-SAH days 1, 2, 3; Fig. 4C).
MMP-9 mediates the protective effect of
minocycline against SAH-induced vasospasm
and neurobehavioral deficits
Consistent with our prior results, WT mice subjected to
SAH exhibited significant cerebral vasospasm and neu-
robehavioral deficits after endovascular perforation SAH,
while vehicle-treated MMP-9/ mice did not develop
significant vasospasm and had milder neurobehavioral
deficits after SAH (Fig. 5A and B). Importantly, the
degree of protection against vasospasm and neurobehav-
ioral deficits in minocycline-treated MMP-9/ mice was
similar to vehicle-treated MMP-9/ mice (MMP-9/:
SAH:Veh vs. MMP-9/:SAH:Mino, P < 0.05 for vasos-
pasm and neurobehavioral deficits, Fig. 5A and B). This
lack of additional protection with minocycline treatment
in MMP-9/ mice suggests that majority of the protec-
tive effect of minocycline is exerted through MMP-9.
Post-SAH minocycline treatment attenuates
SAH-induced vasospasm and
neurobehavioral deficits in mice
To assess the utility of minocycline as a therapeutic agent,
WT mice were administered vehicle or minocycline 2 h
after sham or SAH surgery. Minocycline treatment
afforded significant protection against SAH-induced
vasospasm (P < 0.05 vs. SAH:Vehicle, Fig. 6A) and neu-
robehavioral deficits (P < 0.05 vs. SAH:Vehicle on post-
SAH days 2 and 3, Fig. 6B). Taken together, these results
suggest that treatment with minocycline is a promising
therapeutic strategy against neurovascular dysfunction fol-
lowing SAH.
Figure 3. Minocycline attenuates SAH-induced exacerbation in MMP-
9 activity. WT mice were subjected to sham surgery or endovascular
perforation SAH. MMP-9 activity was assessed in the ipsilateral cortex
at 72 h after SAH by gelatin zymography. (A) Representative
zymogram (B) Data represent mean  SEM. *P < 0.05 vs. Sham #P <
0.05 vs. SAH:Veh,, by Mann–Whitney U test. N = 6 and 5 per group,
respectively.
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Post-SAH minocycline treatment attenuates
SAH-induced microvessel thrombosis
To assess the effect of minocycline on SAH-induced
microvessel thrombosis, WT mice that underwent SAH
were administered vehicle or minocycline every 12 h,
beginning 2 h after surgery. Minocycline-treated mice
developed significantly lesser microvessel thrombosis after
SAH (P < 0.05 vs. SAH:Vehicle, Fig. 7). This result sug-
gests that the protective effect of minocycline against SAH-
induced DCI is through its effect on multiple components.
Minocycline treatment attenuates
vasospasm in a rabbit cisterna magna
injection model of SAH
To further assess the translational potential of
minocycline, we examined its effect in a larger animal
model – the rabbit cisterna magna injection model of
SAH. Vehicle-treated rabbits experienced significant SAH-
induced vasospasm as assessed by basilar artery (BA) area
(P < 0.05 vs. Sham, Fig. 8B) and BA wall thickness
(P < 0.05 vs. Sham, Fig. 8C). In contrast, rabbits that
underwent pre- or post-SAH treatment with minocycline
demonstrated significantly lesser vasospasm (P < 0.05 vs.
SAH:Vehicle, Fig. 8 B and C). These results reaffirm the
therapeutic potential of minocycline.
Discussion
Our study has several new and important findings. First,
genetic deletion of MMP-9 results in significantly less
vasospasm and neurobehavioral deficits in a mouse model
of SAH. Second, pre-SAH administration of the MMP
inhibitor, minocycline, attenuates cerebral vasospasm and
neurobehavioral deficits in murine SAH – a protective
Figure 4. Pre-SAH administration of minocycline attenuates SAH-induced neurovascular dysfunction. WT mice treated with vehicle (Veh) or
minocycline (Mino) were subjected to endovascular perforation SAH. Large artery vasospasm was assessed on post-SAH Day 3 via measurement
of left middle cerebral artery (MCA) diameter. (A) Representative images of left MCA ipsilateral to endovascular perforation (white arrowhead). (B)
Left MCA vessel diameter measurements. Data represent meanSEM. *P < 0.05 by one-way ANOVA with Tukey’s multiple comparisons test. (C)
Neurobehavioral testing was performed at baseline prior to SAH (Day 0) and daily for 3 days via Neuroscore test. Data represent mean  SEM.
*P < 0.05 vs. Sham, and #P < 0.05 vs. SAH:Veh by repeated measures ANOVA with Newman–Keuls multiple comparisons test. N = 8, 13, and 14
for sham, SAH:Veh, and SAH:Mino, respectively.
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Figure 5. MMP-9 mediates minocycline-induced neurovascular protection in SAH. Wild-type (MMP-9+/+) and MMP-9 knockout (MMP-9/) mice
were subjected to sham or endovascular perforation SAH surgery. Mice undergoing SAH were treated with vehicle (Veh) or minocycline (Mino)
starting 2 h prior to SAH. Large artery vasospasm was assessed on post-SAH Day 3 via measurement of left middle cerebral artery (MCA)
diameter. (A) Left MCA vessel diameter measurements. Data represent meanSEM. *P < 0.05 and n.s. P > 0.05 by one-way ANOVA with
Tukey’s multiple comparisons test. (B) Neurobehavioral testing was performed at baseline prior to SAH (Day 0) and daily for 3 days via Neuroscore
test. Data represent mean  SEM. *P < 0.05 vs. MMP-9+/+ Sham, and #P < 0.05 vs. MMP-9+/+:SAH:Veh by repeated measures ANOVA with
Newman–Keuls multiple comparisons test. N = 13, 18, 8, 9, and 9 for MMP-9+/+:Sham, MMP-9+/+:SAH:Veh, MMP-9/:Sham, and MMP-9/:
SAH:Veh and MMP-9/:SAH:Mino, respectively.
Figure 6. Post-SAH administration of minocycline attenuates SAH-induced neurovascular dysfunction. Wild-type mice were subjected to sham or
endovascular perforation SAH surgery. Mice undergoing SAH were treated with vehicle (Veh) or minocycline (Mino) starting 1 h after SAH. Large
artery vasospasm was assessed on post-SAH Day 3 via measurement of left middle cerebral artery (MCA) diameter. (A) Left MCA vessel diameter
measurements. Data represent mean  SEM. *P < 0.05 by one-way ANOVA with Tukey’s multiple comparisons test. (B) Neurobehavioral testing
was performed at baseline prior to SAH (Day 0) and daily for 3 days via Neuroscore test. Data represent meanSEM. *P < 0.05 vs. Sham, and
#P < 0.05 vs. SAH:Veh by repeated measures ANOVA with Newman–Keuls multiple comparisons test. N = 13, 12, and 12 for Sham, SAH:Veh,
and SAH:Mino, respectively.
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effect that is lost in MMP-9 knockout mice. Third,
post-SAH administration of minocycline attenuates
SAH-induced vasospasm and neurological dysfunction in
murine SAH. Fourth, post-SAH administration of
minocycline affords protection against microvessel throm-
bosis in murine SAH and therefore protects against multi-
ple components of DCI. Fifth, pre-SAH and post-SAH
administration of minocycline affords protection against
cerebral vasospasm in a larger, gyrencephalic animal
model of SAH. Taken together, our results provide direct
mechanistic evidence that MMP-9 is a critical player in
the development of cerebral vasospasm and neurobehav-
ioral deficits after SAH, and that minocycline – an already
FDA-approved drug for the treatment of other diseases –
carries significant therapeutic potential to prevent or
reduce the incidence of DCI after SAH.
Two prior laboratory studies have evaluated the role of
MMP-9 in the pathophysiology of cerebral vasospasm
after experimental SAH. Dang et al. examined cultured
rat cerebrovascular smooth muscle cells (SMC) and
observed increased MMP-9 expression and SMC
contraction after exposure to hemolysate.12 The hemoly-
sate-induced increase in MMP-9 expression and SMC
contraction was reduced after pretreatment with SB-3CT,
a non-selective MMP-2 and MMP-9 inhibitor. In a sepa-
rate publication, their group also reported increased
MMP-9 expression in the basilar artery of rats subjected
to cisterna magna injection model of SAH, and showed
that pre-SAH administration of SB-3CT into the cisterna
magna, resulted in decreased vasospasm on Day 3 after
SAH.23 In addition to these two preliminary laboratory
studies, several groups have evaluated the potential role
of MMP-9 in DCI and/or radiographic vasospasm in
SAH patients. Two studies reported higher MMP-9 activ-
ity in the blood,22 CSF,22 and interstitial fluid18 of SAH
patients who developed clinical DCI compared to those
who did not; while another study did not find an associa-
tion between blood MMP-9 levels and clinical DCI.21
Four other studies examined the relationship between
MMP-9 levels and radiographic vasospasm in SAH
patients. Of these, three reported an association between
higher levels of blood MMP-9 and cerebral vasos-
pasm,9,17,33 while the other reported a nonsignificant
trend toward higher CSF MMP-9 levels and cerebral
vasospasm. Taken together, these preclinical and clinical
studies suggest, but do not definitively establish, a role
for MMP-9 in the pathophysiology of vasospasm and
DCI after SAH. In contrast, our finding that SAH-
induced cerebral vasospasm and neurological deficits are
attenuated in MMP-9/ mice provides the most direct
evidence to date that MMP-9 plays a causal role in the
pathogenesis of SAH-induced vasospasm and DCI.
While our study examined the role of MMP-9 in DCI
after SAH, two prior experimental studies have directly
Figure 7. Post-SAH administration of minocycline attenuates SAH-induced microvessel thrombosis. Wild-type mice were subjected to sham or
endovascular perforation SAH surgery. Mice undergoing SAH were treated with vehicle (Veh) or minocycline (Mino) starting 1 h after SAH.
Microvessel thrombosis was assessed by immunohistochemical staining for fibrinogen in brain sections on post-SAH Day 3. (A) Representative
images of brain sections. (B) Microvessel thrombosis was determined as percent coverage of ipsilateral cortex with thrombi. N = 6, 11, and 10 for
Sham, SAH:Veh, and SAH:Mino, respectively. Data represent mean  SEM. *P < 0.05 vs. Sham, #P < 0.05 vs. SAH:Veh, by one-way ANOVA with
Tukey’s multiple comparisons test.
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examined the contribution of MMP-9 to EBI after SAH via
MMP-9 knockout mice. Feiler et al. reported decreased
intracranial pressure and cerebral edema in MMP-9/
mice after endovascular perforation SAH.14 They also
observed a decrease in neurobehavioral deficits on day 2,
and a trend toward decreased neurobehavioral deficits on
days 1 and 3 after endovascular perforation SAH in MMP-
9/ mice. Egashira et al. reported decreased T2 hyperin-
tensity and myelin breakdown in the white matter of
MMP-9/ mice after SAH.13 Their study did not observe
any difference in neurobehavioral deficits between WT and
MMP-9/ on days 1 and 8 after endovascular perforation
SAH. Our observation that MMP-9/ mice develop signif-
icantly less neurobehavioral deficits after SAH on post-SAH
days 2 and 3 (but not on post-SAH day 1) is generally con-
sistent with these prior studies. While Feiler et al. suggest
that the attenuation of SAH-induced neurobehavioral defi-
cits in MMP-9/ mice is a manifestation of decreased
cerebral edema and intracranial pressure seen in their
study, our results suggest that the protection against
delayed onset vasospasm noted in MMP-9/ mice is also a
major contributor to the decreased neurobehavioral deficits
seen in these mice after SAH.
Taken together, our finding that MMP-9 directly con-
tributes to the pathogenesis of vasospasm and neurobe-
havioral deficits after SAH, and prior studies
demonstrating a key role for MMP-9 in pathogenesis of
EBI after SAH, suggest that MMP-9 inhibition represents
an attractive multifaceted therapeutic strategy to combat
SAH-induced neurovascular dysfunction. To examine this
hypothesis, we utilized minocycline, an FDA-approved
semi-synthetic tetracycline antibiotic that exhibits strong
MMP-9 inhibition. In a proof-of-concept experiment, we
found that pre-SAH treatment with minocycline markedly
attenuates cerebral vasospasm and neurobehavioral defi-
cits after SAH. To determine its translational potential,
mice were administered minocycline 2 h after endovascular
perforation SAH. Consistent with the initial proof-of-con-
cept experiment, post-SAH administration of minocycline
significantly attenuated cerebral vasospasm and neurologi-
cal deficits. Importantly, it also reduced SAH-induced
microvessel thrombosis, thus suggesting a protective effect
on nonvasospasm components of DCI that are likely criti-
cal for successful translation of a therapeutic strategy for
SAH. To further examine its translational potential, we
utilized post-SAH administration of minocycline in a
Figure 8. Pre- and Post-SAH minocycline treatment attenuates vasospasm in rabbits. Rabbits were subjected to sham surgery or cisterna magna
double-hemorrhage SAH. The rabbits undergoing SAH were administered vehicle (Veh), minocycline 2 h prior to SAH (Mino-Pre), and 1 h after
SAH (Mino-Post). Vasospasm was assessed by measurement of basilar artery cross-sectional area and wall thickness 5 days after the second
hemorrhage. (A) Representative cross-sectional images of basilar artery. (B) Basilar artery area measurements. Data represent meanSEM.
*P < 0.05 vs. Sham, and # P < 0.05 vs. SAH:Veh by one-way ANOVA with Tukey’s multiple comparisons test. (B) Basilar artery wall thickness
measurements. Data represent mean  SEM. *P < 0.05 vs. Sham, and #P < 0.05 vs. SAH:Veh by one-way ANOVA with Tukey’s multiple
comparisons test.
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rabbit cisterna magna injection model of SAH. Consistent
with our findings in murine SAH, pre-SAH as well as
post-SAH administration of minocycline significantly
attenuated basilar artery vasospasm. These results, in a
larger gyrencephalic animal utilizing a fundamentally dif-
ferent experimental technique for induction of SAH, pro-
vide important cross-validation of the strong therapeutic
potential of minocycline in combating vasospasm and
DCI after SAH. When combined with prior studies
demonstrating the attenuation of EBI16,19,34 and cognitive
deficits19 after SAH with MMP-9 inhibition, the results of
our study suggest that a clinical trial to assess the thera-
peutic effect of minocycline in patients with SAH is war-
ranted.
Conclusion
In this study, we provide definitive mechanistic evidence
that MMP-9 is a key player in the development of cere-
bral vasospasm and DCI after SAH. We also demonstrate
consistent attenuation of SAH-induced neurovascular def-
icits with both pre- and post-SAH administration of
minocycline across different species and experimental
models of SAH, and against multiple components of DCI.
Although additional preclinical testing would be useful,
the excellent safety profile of minocycline in humans and
promising results against both EBI and DCI in experi-
mental SAH studies suggest that a clinical trial in patients
with aneurysmal SAH is the next logical step.
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